Alan J. Kivitz, MD

Altoona Center for Clinical Research
Duncansville, PA, United States

Pres Altoona Arthritis, Osteoporosis and Research Center

Disclosure information not submitted.

Presentation(s):

• 2008: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs

  Sunday, November 13, 2022
  2:35 PM – 2:40 PM Eastern Time

• 2008: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time